Are Commercial Disease Managers Willing and Prepared to Enter the Medicare Market?
Recently, the public policy debate on Medicare reform has turned to adding a prescription drug benefit. Currently, approximately a third of Medicare beneficiaries lack pharmaceutical coverage. Lack of coverage appears to be particularly detrimental to the chronically ill Medicare subpopulation that often needs prescription medications on a daily basis.
Several Congressional proposals would establish disease management demonstration projects concurrently with a prescription drug benefit. Theoretically, implementation of disease management programs that improve coordination of drug therapy with hospital and physician care services would contribute to a more cost-effective drug benefit.
This paper presents results from a Tufts Center for the Study of Drug Development survey describing current disease management practice in the United States. The survey results suggest willingness on the part of commercial disease managers to negotiate performance- and (insurance) risk-based contracts with Medicare. However, at present, disease managers enroll only a small number of Medicare beneficiaries; less than 20% of their total enrollment. Disease managers also have very limited experience with government agency contracts, which comprise less than 5% of their total contracts. In addition, comparatively few disease managers surveyed focus specifically on diseases that are highly prevalent among Medicare beneficiaries, such as Parkinson’s, Alzheimer’s, End-Stage Renal Disease, and Chronic Obstructive Pulmonary Disease. These survey findings suggest that disease managers are not currently fully prepared to enter the Medicare market en masse.
Key WordsDisease management Medicare prescription drug benefit Insurance risk
Unable to display preview. Download preview PDF.
- 1.Zitter M. A new paradigm in health care delivery: disease management. In: Disease Management: A Systems Approach. Todd WE, Nash D, ed. Chicago, IL: American Hospital Association; 1997:2.Google Scholar
- 2.Eggert GM, Friedman B. The need for special interventions for multiple hospital admission patients. Health Care Financ Rev. 1988 Dec (Spec No): 57–67.Google Scholar
- 3.Mueller C, Schur C, O’Connell J. Prescription drug spending: the impact of age and chronic disease status. Am J Public Health. 1997 Oct; 87(3):1627.Google Scholar
- 4.Chen A, Brown R, Archibald N, Aliotta S, Fox PD. Best Practices in Coordinated Care: Submitted to the Health Care Financing Administration Division of Demonstration Programs. Princeton NJ: Mathematica Policy Research; March 22, 2000:3.Google Scholar
- 5.Marmor TR, McKissick G. Medicare’s future: fact, fiction, and folly. Am J Law Medicine. 2000 Summer/Fall;26(2-3):225–253.Google Scholar
- 7.Medicare program: solicitation for proposals for the Medicare Coordinated Care Demonstration. Fed Regist. 2000 Jul 28; 65(146):46466–46473.Google Scholar
- 8.Providing coordinated care to improve quality of care for chronically ill Medicare beneficiaries. Medicare Fact Sheet. Washington DC: Health Care Financing Administration; Jan 19, 2001.Google Scholar
- 9.HCFA announces sites for new Coordinated Care Demonstration to improve care to chronically ill. Medicare News. Washington DC: Health Care Financing Administration; Jan 19, 2001.Google Scholar
- 10.Medicare Coordinated Care Demonstration, www.hcfa.gov/research/coorcare/htm.
- 11.HCFA extends Medicare demonstration with United Mine Workers of America health and retirement funds. Medicare News. Washington DC: Health Care Financing Administration; Jan 19, 2001.Google Scholar
- 12.Medicare Rx 2000 Act (HR 4680). 106th Congress 2d Session. June 15, 2000.Google Scholar
- 13.Congressional Budget Office cost estimate: H.R. 4680: Medicare Rx 2000 Act.www.cbo.gov.
- 14.Medicare Rx disease management pilot project estimated to cost $300 mil. Pink Sheet. July 10, 2000; 62(28):7–8.Google Scholar
- 15.Medicare Rx should offer choice of PBMs, drug plan designs, PCMA says. Pink Sheet. July 2, 2001; 63(27):6.Google Scholar